Current Report Filing (8-k)
November 08 2016 - 8:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event
Reported): November 8, 2016
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
|
|
|
18th Floor, Jialong International Building
|
19 Chaoyang Park Road
|
Chaoyang District, Beijing 100125
|
People’s Republic of China
|
(Address of Principal Executive Offices)
86-10-6598-3111
Registrant's telephone number, including
area code
____________________________________________________________
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
ITEM 8.01. OTHER EVENTS.
On November 8, 2016, Guizhou Taibang Biological Products Co.
Ltd. (“Guizhou Taibang”), a wholly-owned subsidiary of China Biologic Products, Inc. (the “Company”), completed
the capital withdrawal of its two former minority shareholders by paying the remaining balance of the consideration pursuant to
an agreement dated July 31, 2016, a summary English translation of which was filed as an exhibit to the Company’s current
report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2016.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 8, 2016
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
|
|
By:
|
|
/s/ David (Xiaoying) Gao
|
|
|
|
|
David (Xiaoying) Gao
|
|
|
|
|
Chief Executive Officer
|
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Apr 2023 to Apr 2024